| Serial Number | 79437611 |
| Word Mark | TARGED TARGETED ENZYME DELIVERY |
| Filing Date | Friday, August 22, 2025 |
| Status | 681 - PUBLICATION/ISSUE REVIEW COMPLETE |
| Status Date | Tuesday, April 21, 2026 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 3 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s) |
| Published for Opposition Date | Tuesday, May 12, 2026 |
| Description of Mark | The mark consists of the word "TARGED" in stylized font wherein the letters "TARG" are in aqua green and the letters "ED" are in dark green, with a dark green arrow forming the middle arm of the "E"; below this word is the wording "TARGETED ENZYME DELIVERY" in stylized grey font. |
| Indication of Colors claimed | The colors aqua green, dark green and grey are claimed as a feature of the mark. |
| Goods and Services | Scientific and technological services, namely, research and design in the field of medicine and pharmaceuticals; research and development services in the field of medicine and pharmaceuticals; scientific research in the nature of conducting laboratory and clinical testing for others; biotechnology research services; pharmaceutical research services; medical and scientific laboratory services; medical research and development services; research and development in the field of thrombosis treatment; pharmaceutical and biotechnology research for antithrombotic drugs; scientific research in the nature of conducting preclinical and clinical trials for others in the field of drugs for diseases associated with thrombosis; d r u g discovery services related to thrombosis; development of biopharmaceuticals for cardiovascular diseases; scientific research in the field of platelet aggregation inhibitors; consultancy services in pharmaceutical research and development; conducting scientific studies related to thrombosis-related and blood clotting disorders; scientific research in the nature of conducting clinical trials for others in the field of thrombosis-related drugs and therapies; design and development of drug efficacy studies for treatment of diseases associated with thrombosis; genetic research and molecular biology research services related to thrombosis; technical data analysis of scientific research and providing temporary use of online, non-downloadable computer software for use in modeling in the field of treatment of diseases associated with thrombosis; laboratory research services for thrombosis-related diagnosis and testing; research services related to anticoagulation therapy; research in personalized medicine for patients of diseases associated with thrombosis patients; quality assessment, namely, reference material certification services being the testing, analysis and evaluation of the goods of others to determine conformity with certification standards in the field of treatment of diseases associated with thrombosis treatment; research and development services for biotechnological solutions for diseases associated with thrombosis; scientific advisory and consultation services in thrombosis-related research |
| Goods and Services | Pharmaceutical preparations for the treatment of diseases associated with thrombosis; medical preparations for the treatment of diseases associated with thrombosis; dietary supplements for medical purposes; medicinal herbs and medicinal herbal extracts; drugs for medical purposes for the treatment of diseases associated with thrombosis, pharmaceutical preparations for the prevention and treatment of diseases associated with thrombosis; pharmaceutical preparations being antithrombotic agents; thrombolytic drugs; pharmaceutical preparations being coagulation inhibitors; anticoagulants; pharmaceutical preparations in the nature of platelet aggregation inhibitors; pharmaceutical preparations in the nature of hemostatic agents; pharmaceutical preparations, namely, blood thinners for medical use; therapeutic compounds for diseases associated with thrombosis; pharmaceutical preparations for cardiovascular diseases; pharmaceutical preparations for blood clotting disorders; injectable or intravenous medicinal solutions for thrombosis-related treatment; medicinal preparations for the treatment of deep vein thrombosis (DVT); medicinal preparations for pulmonary embolism (PE) management; preclinical or clinical trial medicines for thrombosis-related treatment research; pharmaceuticals for vascular diseases |
| NOT AVAILABLE | "TARGETED ENZYME DELIVERY" |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, November 27, 2025 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, November 27, 2025 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | TargED Biopharmaceuticals B.V. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 24 - NOT AVAILABLE |
| Address | NL |
| Event Date | Event Description |
| Thursday, November 27, 2025 | SN ASSIGNED FOR SECT 66A APPL FROM IB |
| Friday, November 28, 2025 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Friday, November 28, 2025 | APPLICATION FILING RECEIPT MAILED |
| Wednesday, January 7, 2026 | ASSIGNED TO EXAMINER |
| Wednesday, January 14, 2026 | NON-FINAL ACTION WRITTEN |
| Thursday, January 15, 2026 | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
| Wednesday, February 11, 2026 | REFUSAL PROCESSED BY MPU |
| Thursday, February 12, 2026 | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |
| Thursday, February 26, 2026 | REFUSAL PROCESSED BY IB |
| Tuesday, April 14, 2026 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Tuesday, April 14, 2026 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Tuesday, April 14, 2026 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Tuesday, April 14, 2026 | EXAMINERS AMENDMENT -WRITTEN |
| Tuesday, April 14, 2026 | EXAMINERS AMENDMENT E-MAILED |
| Tuesday, April 14, 2026 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Tuesday, April 14, 2026 | EXAMINER'S AMENDMENT ENTERED |
| Tuesday, April 14, 2026 | APPROVED FOR PUB - PRINCIPAL REGISTER |